Patents Examined by Brian Whiteman
  • Patent number: 10994025
    Abstract: The invention relates to methods of improving efficacy and enhancing silencing of target genes using Ago2 protein-dsRNA complex (RNP) of the invention.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 4, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Jiahe Li, Paula T. Hammond, Yanpu He, Wade Wang
  • Patent number: 10961532
    Abstract: Methods for reactivating genes on the inactive X chromosome that include administering one or both of a DNA methyltransferase (DNMT) Inhibitor and/or a topoisomerase inhibitor, e.g., etoposide and/or 5-azacytidine (aza), optionally in combination with an inhibitor of XIST RNA and/or an Xist-interacting protein, e.g., a chromatin-modifying protein, e.g., a small molecule or an inhibitory nucleic acid (such as a small inhibitory RNA (siRNAs) or antisense oligonucleotide (ASO)) that targets XIST RNA and/or a gene encoding an Xist-interacting protein, e.g., a chromatin-modifying protein.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 30, 2021
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Anand Minajigi, Lieselot Carrette
  • Patent number: 10961535
    Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 30, 2021
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Christine Esau, Padmanabh Chivukula
  • Patent number: 10961531
    Abstract: Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: March 30, 2021
    Assignee: AgeX Therapeutics, Inc.
    Inventors: Michael D. West, Karen Chapman, Hal Sternberg
  • Patent number: 10953034
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 23, 2021
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Patent number: 10954517
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 23, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 10954519
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: March 23, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier
  • Patent number: 10947540
    Abstract: The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2.
    Type: Grant
    Filed: November 19, 2017
    Date of Patent: March 16, 2021
    Inventors: Marc Bitoun, Delphine Trochet, Bernard Prudhon
  • Patent number: 10947544
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: March 16, 2021
    Assignee: Archemix LLC
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • Patent number: 10941402
    Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: March 9, 2021
    Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
  • Patent number: 10941401
    Abstract: Provided herein are synthetic nucleic acid molecules and methods of using such synthetic nucleic acid molecules for strong repression of target gene expression. In particular, provided herein are methods for altering expression of a protein in a cell, where the method comprises introducing into a cell a protein coding sequence operably linked to a near-threshold translational repressor having first and second trigger recognition sequences that are fully or partially complementary to a repressing trigger RNA; and introducing into a cell the repressing trigger RNA.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: March 9, 2021
    Inventors: Alexander Green, Yu Zhou
  • Patent number: 10941209
    Abstract: Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 9, 2021
    Assignees: Albert Einstein College of Medicine, British Columbia Cancer Agency Branch
    Inventors: Ulrich Steidl, Christian Steidl, Ujunwa Cynthia Okoye-Okafor
  • Patent number: 10941403
    Abstract: MicroRNA inhibitors as anti-cancer therapeutics are described. The microRNA inhibitors can inhibit microRNA-15a and can mimic the effects of higher dose radiation at lower doses. Other benefits are also described.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: March 9, 2021
    Assignee: Oregon Health & Science University
    Inventors: Sudarshan Anand, Shushan Rana, Charles R. Thomas, Jr.
  • Patent number: 10934543
    Abstract: Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass decrease, even for the elderly and even without requiring exercise, by inducing muscle differentiation. Provided is a composition for treating or preventing disorders or diseases associated with muscle atrophy, or for promoting muscle regeneration, the composition comprising, as an active ingredient, an inducer of muscle differentiation consisting of miR-199 or DNA that contains miR-199 gene encoding the miR-199.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 2, 2021
    Inventors: Hirohiko Hohjoh, Masashi Fukuoka
  • Patent number: 10933080
    Abstract: The present invention relates to a composition comprising a Ttyh1 gene expression inhibitor or a Ttyh1 protein activity inhibitor, and a method of preventing or treating Alzheimer's disease using the same.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: March 2, 2021
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: Keejung Yoon, Juwan Kim
  • Patent number: 10927373
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 23, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Patent number: 10912791
    Abstract: Provided herein are nanoparticles comprising antisense-encoded erythropoietin receptor (RopE) alone or in combination with erythropoietin receptor (EpoR). Also provided herein are methods of treating or preventing lungs disorders comprising administering RopE alone or in combination with EpoR.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: February 9, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Connie Hsia, Orson W. Moe, Kytai Nguyen
  • Patent number: 10907161
    Abstract: The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: February 2, 2021
    Assignee: Checkmate Pharmaceuticals, Inc.
    Inventors: Arthur M. Krieg, Aaron Jay Morris
  • Patent number: 10900091
    Abstract: The present invention provides methods for assessing the likelihood of effectiveness of chemotherapy such as oxaliplatin treatment in colorectal cancer patients as well as their survival prospect by determining the level of miR-133a in the cancer tissue. A kit useful for such methods are also provided.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 26, 2021
    Assignee: The Chinese University of Hong Kong
    Inventors: Siu Man Simon Ng, Jun Yu, Joseph Jao Yiu Sung, Yujuan Dong
  • Patent number: 10889864
    Abstract: Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are non-coding RNAs as diagnostic markers and clinical targets for cancer.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: January 12, 2021
    Inventors: Arul Chinnaiyan, Felix Y. Feng, John Prensner, Matthew Iyer, Yashar Niknafs